US Stock MarketDetailed Quotes
DRRX Durect
- 0.9125
- -0.0234-2.50%
Close Nov 27 16:00 ET
- 0.9125
- 0.00000.00%
Post 20:02 ET
28.33MMarket Cap-1425P/E (TTM)
0.9716High0.9125Low35.73KVolume0.9332Open0.9359Pre Close33.70KTurnover0.13%Turnover RatioLossP/E (Static)31.04MShares1.880052wk High23.40P/B26.18MFloat Cap0.481052wk Low--Dividend TTM28.69MShs Float185.0000Historical High--Div YieldTTM6.32%Amplitude0.4703Historical Low0.9420Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Durect Stock Forum
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
DURECT (DRRX) has sold its ALZET® osmotic pumps product line to Lafayette Instrument Co. for $17.5 million. The transaction includes certain assets and liabilities associated with the ALZET line.
DURECT used the proceeds to pay off its remaining obligations under the Oxford Finance term loan.
The company states this sale strengthens its cash position and extends runway t...
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design
- Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint;topline results expected within two years of trial initiation
- Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b tr...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
loading...
loading...
In a significant move within the biopharmaceutical industry, DURECT Corporation (DRRX) has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. This alliance, announced on March 4, 2024, is set to jointly market and commercialize the ALZET Osmotic Pumps ...
No comment yet